BENIGN PROSTATIC HYPERPLASIA TREATMENTS
Generic Brand Strength Form Dose Note
5 ALPHA-REDUCTASE INHIBITORS1
dutasteride Avodart 0.5mg caps 0.5mg once daily

• Inhibits type I (liver, skin) and II (genitourinary) 5 alpha-reductase

• >90% suppression of baseline serum DHT
finasteride Proscar 5mg tabs 5mg once daily

• Inhibits type II (genitourinary) 5 alpha-reductase

Continue Reading

• 70% suppression of baseline serum DHT
ALPHA1-BLOCKERS2,3
alfuzosin Uroxatral 10mg ext‑rel 
tabs		 10mg daily

• Swallow whole

• Take after same meal each day

• Dose titration not needed
doxazosin Cardura 1mg, 
2mg, 4mg, 8mg		 scored
tabs		 Initially 1mg daily; may double dose every 1−2wks; max 8mg daily  
Cardura 
XL		 4mg, 8mg ext‑rel 
tabs		 Initially 4mg daily; may titrate after 3−4wks; max 8mg daily

• Swallow whole

• Take with breakfast
silodosin Rapaflo 4mg, 8mg caps 8mg once daily

• Take with a meal

• Renal impairment (CrCl 30−50mL/min): 4mg
tamsulosin Flomax 0.4mg caps Initially 0.4mg daily; may increase to 0.8mg daily after 2−4wks

• Swallow whole

• Take ½ hr after same meal each day
terazosin — 1mg, 2mg, 5mg, 10mg caps Initially 1mg daily; max 20mg daily

• Give at bedtime
PHOSPHODIESTERASE TYPE 5 INHIBITOR
tadalafil Cialis 2.5mg, 5mg, 10mg*, 20mg* tabs 5mg taken at approxi–
mately the same time every day

• Also indicated for erectile dysfunction + BPH: take without regard to timing of sexual activity.

• Moderate renal dysfunction (CrCl 30−50mL/min): Initially 2.5mg, may increase to 5mg.

• Severe renal dysfunction (CrCl <30mL/min): not recommended.

• Mild or moderate hepatic impairment: use caution; severe: not recommended.

• Concomitant alpha blockers: not recommended.

• Concomitant potent CYP3A4 inhibitors: max 2.5mg.
TYPE I and II 5 ALPHA-REDUCTASE INHIBITORS1 & ALPHA1‑BLOCKER2,3
dutasteride
+ 
tamsulosin		 Jalyn 0.5mg +
 0.4mg		 caps 1 cap once daily

• Swallow whole

• Take ½ hr after same meal each day
NOTES

* These strengths are not indicated for use in BPH.

¹5AR inhibitors lower prostate specific antigen (PSA) levels in a predictable fashion, adjust interpretation of PSA levels accordingly.

²α1-blockers may cause orthostatic hypotension; titrate dose slowly. When therapy has been interrupted for several days or longer, patients should be retitrated from the initial dose.

³Although rare, priapism and subsequent permanent impotence has been associated with the use of α1‑blockers and patients should be fully informed of this risk.

Not an inclusive list of medications. Please see drug monograph at www.eMPR.com and/or contact company for full drug labeling.

(Rev. 11/2017)

This article originally appeared on MPR

Topics:

Chart Urologic Disorders